Filtered By:
Drug: Lipitor
This page shows you your search results in order of date.
Order by Relevance | Date
Total 101 results found since Jan 2013.
Statins and immune-mediated necrotizing myopathy: Variability in the risk
CONCLUSION: Atorvastatin presents the highest risk of IMNM. Our data suggest that the occurrence of IMNM is a class effect.PMID:37625939 | DOI:10.1016/j.therap.2023.07.005
Source: Therapie - August 25, 2023 Category: Psychiatry & Psychology Authors: Thierry Trenque Jed Hadjoudj Agathe Trenque Federica Tralongo Salom é Martin Brahim Azzouz Source Type: research
Development and validation of an eco-friendly HPLC –UV method for determination of atorvastatin and vitamin D3 in pure form and pharmaceutical formulation
Statin-associated muscle symptoms are considered as obvious adverse effects of prolonged statin therapy such as myopathy, myalgia, and rhabdomyolysis. These side effects are associated with vitamin D3 deficiency ...
Source: Chemistry Central Journal - June 20, 2023 Category: Chemistry Authors: Khaled Maged, Magda M. El-Henawee and Soad S. Abd El-Hay Tags: Research Source Type: research
Statin associated Muscular Adverse Effects
CONCLUSION: Early recognition of muscle symptoms is required to prevent rhabdomyolysis. Further researchare needed to completely elucidate the pathophysiology of statin-induced muscular adverse effects.PMID:36847228 | DOI:10.2174/1574886318666230227143627
Source: Current Drug Safety - February 27, 2023 Category: Drugs & Pharmacology Authors: Rania Kammoun Ons Charfi Ghozlane Lakhoua Ahmed Zaiem Riadh Daghfous Sarrah Kastalli Imen Aouinti Sihem El Aidli Source Type: research
Drug –Drug Interaction of the Sodium Glucose Co-Transporter 2 Inhibitors with Statins and Myopathy: A Disproportionality Analysis Using Adverse Events Reporting Data
ConclusionsReports of myopathy were not disproportionally higher among those using SGLT-2i with statins compared to SGLT-2i or statins alone at the class level. Further observational studies may be needed to better assess this interaction at the agent level.
Source: Drug Safety - March 5, 2022 Category: Drugs & Pharmacology Source Type: research
Rhabdomyolysis due to warfarin and atorvastatin combination therapy in a patient with ischemic heart disease: (A drug interaction)
CONCLUSION: Statins are widely prescribed to patients with cardiovascular problems. Therefore, clinicians should pay attention to the patient's medical history, current prescribed doses, and drug interactions when adding new drugs or adjusting existing drugs.PMID:35242328 | PMC:PMC8861410 | DOI:10.1016/j.amsu.2022.103384
Source: Annals of Medicine - March 4, 2022 Category: Internal Medicine Authors: Saeed Kargar Soliemanabad Kimia Rasouli Zakaria Zakariaei Mostafa Soleymani Parastoo Karimi Aliabadi Source Type: research
A systematic review of the drug –drug interaction between statins and colchicine: Patient characteristics, etiologies, and clinical management strategies
AbstractColchicine and statins are frequently co-prescribed for prevention and treatment of cardiovascular diseases, auto-inflammatory diseases, and gout. Both are substrates and inhibitors of the cytochrome P-450 (CYP) 3A4 isozyme and P-glycoprotein so that taken together, they represent a clinically significant interaction. Data suggest the interaction may be associated with potentially life-threatening myopathies and rhabdomyolysis. The purposes of this systematic review (SR) were to gather and appraise evidence surrounding the statin-colchicine drug interaction and discuss related risk-mitigation strategies. An electro...
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - February 27, 2022 Category: Drugs & Pharmacology Authors: Nicholas C. Schwier,
Cyrille K. Cornelio,
Paul M. Boylan Tags: REVIEW Source Type: research
A systematic review of the drug ‐drug interaction between statins and colchicine: patient characteristics, etiologies, and clinical management strategies
AbstractColchicine and statins are frequently co-prescribed for prevention and treatment of cardiovascular diseases, auto-inflammatory diseases, and gout. Both are substrates and inhibitors of the cytochrome P-450 (CYP) 3A4 isozyme and P-glycoprotein so that taken together, they represent a clinically significant interaction. Data suggest the interaction may be associated with potentially life-threatening myopathies and rhabdomyolysis. The purposes of this systematic review (SR) were to gather and appraise evidence surrounding the statin-colchicine drug interaction and discuss related risk-mitigation strategies. An electro...
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - February 18, 2022 Category: Drugs & Pharmacology Authors: Nicholas C. Schwier,
Cyrille K. Cornelio,
Paul M. Boylan Tags: REVIEW Source Type: research
